API Gallery
The Iodoquinol market is projected to grow at a CAGR of 5.2% between 2025 and 2035, driven by increasing applications in pharmaceutical formulations for gastrointestinal health management and its use as a stabilizer and binder in drug formulations.
The Iohexol market is projected to grow at a CAGR of 6.5% during the forecast period 2025–2035. This growth is primarily driven by the increasing demand for contrast agents in imaging procedures such as CT scans, X-rays, and angiograms, along with expanding applications in diagnostic research and clinical settings.
The Iopamidol market is expected to grow at a CAGR of 6.2% between 2025 and 2035. The growth is driven by increasing demand for advanced diagnostic imaging procedures such as CT scans, angiography, and X-rays, where Iopamidol is widely used as a contrast agent.
The Ipilimumab market is projected to grow at a CAGR of 6.1% between 2025 and 2035. Growth is primarily driven by the rising global burden of cancers such as melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, where immunotherapies like Ipilimumab play a critical role.
The Ipragliflozin market is projected to grow at a CAGR of 6.8% between 2025 and 2035. This growth is driven by the rising prevalence of type 2 diabetes globally, increasing preference for SGLT2 inhibitors due to cardiovascular and renal benefits, and expanding adoption of combination therapies.
The Ipratropium Bromide market is projected to grow steadily between 2025 and 2035, at a CAGR of 5.9%. This growth is driven by the increasing prevalence of respiratory diseases such as COPD, asthma, and rhinitis, alongside rising demand for effective bronchodilator therapies.
The Global Iron (III) Hydroxide Polymaltose Complex market is expected to grow steadily, at a CAGR of 5.5% during the forecast period 2025-2035. This growth is primarily driven by the increasing prevalence of iron deficiency anemia across various demographics, growing awareness of iron supplementation, and rising demand for safer, better-tolerated iron therapies.
The Isoxsuprine Hydrochloride market is projected to grow steadily between 2025 and 2035, at a CAGR of 4.2%. This growth is primarily driven by the increasing incidence of peripheral vascular diseases, preterm labor cases, cerebrovascular disorders, and rising pharmaceutical demand for smooth muscle relaxants.
The Istradefylline market is projected to grow steadily between 2025 and 2035, with a CAGR of 7.2%. This growth is driven by the increasing prevalence of Parkinson’s disease, advancements in pharmaceutical research, and rising demand for effective treatment options.
The Itopride Hydrochloride market is projected to grow at a CAGR of 6.3% during the forecast period 2025–2035, driven by the increasing prevalence of gastrointestinal disorders, particularly functional dyspepsia and gastroparesis.
The Lercanidipine market is projected to grow at a CAGR of 6.5% during the forecast period 2025–2035. This growth is primarily driven by the increasing prevalence of cardiovascular diseases, especially hypertension and coronary artery disease, where Lercanidipine plays a vital role.
The Letermovir market is projected to grow at a steady CAGR of 7.8% between 2025 and 2035. This growth is primarily driven by the increasing prevalence of cytomegalovirus (CMV) infections, particularly in transplant patients, and the expanding use of Letermovir as a prophylactic treatment.
The Letrozole market is projected to grow steadily between 2025 and 2035, at a CAGR of 5.1%. This growth is driven by the increasing prevalence of breast cancer, particularly among women aged 40 and above, along with the rising demand for fertility treatments, especially in women with ovulatory disorders.
The Itraconazole market is projected to grow steadily between 2025 and 2035, with a CAGR of 7.5%. This growth is driven by the increasing prevalence of fungal infections, particularly among immunocompromised patients, and the rising demand for effective antifungal treatments.
The global Leuprolide Acetate market is projected to grow at a CAGR of 5.7% between 2025 and 2035. This growth is primarily driven by the increasing prevalence of hormone-sensitive conditions such as prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
Search from 10,000 + API reports
How can we help you?
Reach out to discuss how our team can help your business achieve real results.
